Michael L Maitland

Get Real: Integration of Real‐World Data to Improve Patient Care

Ron J Keizer, Erik Dvergsten, Andrej Kolacevski, 2020, Clinical pharmacology and therapeutics.

Cancer Clinical Investigators Should Converge with Pharmacometricians

Michael L Maitland, Roisin E O'Cearbhaill, Jogarao Gobburu, 2019, Clinical Cancer Research.

Comparison of tumor size assessments in tumor growth inhibition-overall survival models with second-line colorectal cancer data from the VELOUR study

Binsheng Zhao, Sanja Karovic, Michael L Maitland, 2018, Cancer Chemotherapy and Pharmacology.

Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis

Michael L Maitland, M. Maitland, 2010, Clinical Cancer Research.

Analysis of the Yield of Phase II Combination Therapy Trials in Medical Oncology

Michael L Maitland, Mark J Ratain, M. Maitland, 2010, Clinical Cancer Research.

RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point.

Michael L Maitland, Mark J Ratain, M. Maitland, 2012, Cancer research.

Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

Soma Das, Federico Innocenti, Michael L Maitland, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.

Michael L Maitland, Walter M Stadler, Mark J Ratain, 2007, Journal of the National Cancer Institute.

Terminal Ballistics of Kinase Inhibitors: There Are No Magic Bullets

Michael L Maitland, Mark J Ratain, M. Maitland, 2006, Annals of Internal Medicine.

Interpreting disparate responses to cancer therapy: the role of human population genetics.

Michael L Maitland, Mark J Ratain, M. Maitland, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.